Hi Mephis
Tony Barber is very wrong on this.
There's already a bunch of Aussie biotechs listed on the ASX and with ADRs (American Depository Reserves) trading on the NASDAQ. Most of which earn very little or no revenue and have market caps similar to NEU.
This includes Immutep (formerly Prima Biomed), Immuron, Genetic Technologies and Kazia Therapeutics all listed on the Nasdaq (Mesoblast and Opthea are on the bigger end of the market cap scale also listed).
Although - being dual listed hasn't really helped any of these companies reach significant heights, as they're still able to be pulled down and manipulated on the ASX.
But they do get access to US investors and capital. For example Blackrock is now heavily invested in Immutep via its access to the NASDAQ.
Ann: Neuren corporate presentation, 24 February 2021, page-28
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.65 |
Change
-0.540(2.81%) |
Mkt cap ! $2.383B | |||
| Open | High | Low | Value | Volume |
| $18.98 | $19.15 | $18.50 | $10.51M | 560.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1500 | $18.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.65 | 1127 | 2 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |